Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to ...

ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...

Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.

Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.

Natural killer cells, also referred to as NK cells, play several major roles in the body's defense against cancers like renal cell carcinoma. Natural killer cells, also referred to as NK cells, play ...

A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and didn't hint ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...

Creative Biolabs today announced the upgrade of its next-generation drug discovery pipeline with integrated AI-driven ...